ACE inhibitors and angiotensin II receptor antagonists in Crohn’s disease management

Abstract

An increasing repertoire of therapeutic indications for the angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has followed an explosion of research exploring the role of the proinflammatory and profibrotic renin–angiotensin–aldosterone system in numerous organ systems. This evidence also implicates the renin–angiotensin–aldosterone system in the pathogenesis of other chronic inflammatory and fibrotic disorders, such as Crohn’s disease. While the research to date supports this hypothesis, further investigation of the renin–angiotensin–aldosterone system in human Crohn’s disease is required before these agents can realistically be investigated in human trials.

Keywords::

• angiotensin-converting enzyme inhibitor
• angiotensin II receptor antagonist
• Crohn’s disease
• renin–angiotensin–aldosterone system
• TGF-β

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.